{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:59:30Z","timestamp":1762505970512,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jaad.2012.06.045","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T14:30:14Z","timestamp":1346337014000},"page":"1375-1379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma"],"prefix":"10.1016","volume":"67","author":[{"given":"Kevin P.","family":"Boyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethaney","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleodor","family":"Andea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Martin","family":"Conry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Hughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2012.06.045_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2012.06.045_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.06.045_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.06.045_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract 8509]","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation positive metastatic melanoma [abstract]","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.06.045_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.06.045_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","author":"Huang","year":"2012","journal-title":"Arch Dermatol Published online"},{"key":"10.1016\/j.jaad.2012.06.045_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib12","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1200\/JCO.2010.31.3783","article-title":"Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib","volume":"28","author":"Franck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1365-4632.2010.04606.x","article-title":"Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib","volume":"49","author":"Sahai","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2009.02.004","article-title":"Array of cutaneous adverse effects associated with sorafenib","volume":"61","author":"Kong","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2012.06.045_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-011-0198-4","article-title":"The \u201cSWOT\u201d of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors, or both?","volume":"13","author":"Nissan","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaad.2012.06.045_bib21","unstructured":"Hoffmann-La Roche. A study of RO5185426 And GDC-0973 in patients with BRAF-mutation positive metastatic melanoma. Available from:\u00a0URL:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01271803. Accessed February 4, 2012."},{"issue":"Suppl","key":"10.1016\/j.jaad.2012.06.045_bib22","article-title":"Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]","volume":"29","author":"Infante","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2012.06.045_bib23","first-page":"753","article-title":"Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients","volume":"9","author":"Marquez","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2012.06.045_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-8-27","article-title":"Identification of the B-Raf\/Mek\/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion","volume":"8","author":"Cheepala","year":"2009","journal-title":"Mol Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221200789X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221200789X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:26:54Z","timestamp":1759271214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221200789X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S019096221200789X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2012.06.045","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.04.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}